Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周低点，触及0.22美元。这一显著下跌反映了公司正经历艰难时期，该股票一年内下跌了85.8%。根据 InvestingPro 数据显示，公司市值已萎缩至仅124万美元，而技术指标表明该股票处于超卖区域。投资者目睹了公司市值在过去一年中的急剧下降，因为该股票在市场压力和行业特定逆风中 ...

Investing.com — Processa Pharmaceuticals Inc. (PCSA)股价已跌至52周新低，触及$0.36。这一显著下跌反映了公司正经历艰难时期，过去一年股价暴跌了-84.39%。根据 InvestingPro 数据，公司市值已萎缩至仅220万美元，而在过去十二个月中录得负EBITDA为-1205万美元。投资者一直密切关注公司表现，这一新低点标志着对其未来前景和市 ...

Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.74) EPS for the quarter, beating analysts ...

Processa Pharmaceuticals Inc. (PCSA) shares have tumbled to a 52-week low, touching down at $0.8, marking a significant downturn for the micro-cap company currently valued at just $2.68 million.

Processa Pharmaceuticals has a one year low of $0.40 and a one year high of $3.31. The company has a market capitalization of $1.39 million, a price-to-earnings ratio of -0.13 and a beta of 0.75 ...

Shares of Processa Pharmaceuticals (NASDAQ:PCSA) rallied 46% Tuesday after the company said the FDA had cleared its application to initiate a Phase 2 study of its next-generation capecitabine drug, or ...

HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals, Inc. HANOVER, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company ...

Financial Health for Processa Pharmaceuticals is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next generation of chemotherapeutic drugs ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...